

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 16:34
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
--------------------------	--------	------	-----------------	--------

HAEMATOLOGY

**CITICARE PULSEFIT PACKAGE
COMPLETE BLOOD COUNT (CBC)**

EDTA Whole Blood

HEMOGLOBIN	12.1	g/dL	12 - 15.5	Colorimetric
RBC COUNT	4.31	10 ⁶ /uL	3.5 - 5.5	EI
HEMATOCRIT	36.9	%	37 - 54	Calculation
MCV	85.5	fL	80 - 100	Calculation
MCH	27.9	pg	27 - 34	Calculation
MCHC	32.7	g/dL	32 - 36	Calculation
RDW	14.4	%	11 - 16	Calculation
MPV	11	fL	8 - 12	Calculation
PLATELET COUNT	267	10 ³ /uL	140 - 450	EI
WBC COUNT	9.41	10 ³ /uL	4 - 10	EI

DIFFERENTIAL COUNT (DC)

EDTA Whole Blood

NEUTROPHILS	62	%	50 - 70	Flow Cytometry
LYMPHOCYTES	26.9	%	20 - 40	Flow Cytometry
EOSINOPHILS	2.6	%	0.5 - 5	Flow Cytometry
MONOCYTES	8.3	%	3 - 12	Flow Cytometry
BASOPHILS	0.2	%	0 - 1	Flow Cytometry
ABSOLUTE NEUTROPHIL COUNT	5.83	10 ³ cells/uL	2 - 7	
ABSOLUTE LYMPHOCYTE COUNT	2.54	10 ³ cells/uL	0.8 - 4	
ABSOLUTE MONOCYTE COUNT	0.77	10 ³ cells/uL	0.12 - 1.2	
ABSOLUTE EOSINOPHIL COUNT	0.25	10 ³ cells/uL	0.02 - 0.5	
ABSOLUTE BASOPHIL COUNT	0.02	10 ³ cells/uL	0 - 0.1	

Prepared By



Roshini

Medical Laboratory Technologist



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

Page 1 of 8

End Of The Report

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 18:46
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
CLINICAL BIOCHEMISTRY				
CITICARE PULSEFIT PACKAGE				
GLUCOSE (FASTING)	103	mg/dL	70 - 110	GOD - POD
Fluoride Plasma				
GLYCATED HEMOGLOBIN (HbA1C) ^				
EDTA Whole Blood				
HBA1C	4.9	%	Normal:4.6-5.6 Prediabetes: 5.7- 6.4 Diabetes: >6.5	HPLC
eAG (estimated Average Glucose)	94	%		Calculation
BLOOD UREA NITROGEN (SERUM)				
Serum				
UREA	36.7	mg/dL	16.87 - 43.37	Urease-glutamate Dehydrogenase, UV method
BUN	17.1	mg/dL	7 - 18	Calculation
CREATININE	0.75	mg/dL	0.5 - 1.1	Sarcosine Oxidase
Serum				
BUN/CREATININE RATIO	22.80	NULL	Prerenal: > 20:1 Normal or Postrenal: 10-20:1 Intrarenal: < 10:1	Calculation
Serum				
URIC ACID	5.7	mg/dL	1.9 - 7.5	Uricase - POD
Serum				
IRON	50.2	ug/dL	37 - 145	Ferrozine
Serum				
CHOLESTEROL (TOTAL)	139.1	mg/dL	Desirable: < 200 Borderline High: 200 - 239 High: > 239	CHOD-POD
Serum				
NON-HDL CHOLESTEROL	101.2	mg/dL	< 140	Calculation
Serum				

Prepared By



Roshini

Medical Laboratory Technologist



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

Page 2 of 8

End Of The Report

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 18:46
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
CLINICAL BIOCHEMISTRY				
CITICARE PULSEFIT PACKAGE				
TRIGLYCERIDES	299.3	mg/dl	Normal: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High: > 499	GPO-POD
Serum HDL CHOLESTEROL	37.9	mg/dL	Optimum>60 Borderline : 50-59 High risk : <50	Direct
Serum LDL CHOLESTEROL	95.9	mg/dl	Optimal: < 100 Near/Above Optimal: 100 - 129 Borderline High: 130 - 159 High: 160 - 189 Very High: > 189	Direct
Serum VLDL CHOLESTEROL	59.86	mg/dL	0 - 30	Calculation
Serum LDL / HDL RATIO	2.5	--	< 3.5	Calculation
Serum				

Prepared By



Roshini

Medical Laboratory Technologist



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

Page 3 of 8

End Of The Report

CONFIDENTIAL LABORATORY REPORT

Patient Name : **Ms. NAHLA** Request Date : 21/05/2025 15:26
Age / Sex : 15 Y / Female Collected Date : 21/05/2025 14:57
DOB : Acceptance Date : 21/05/2025 15:34
Referral Doctor : Report Date : 21/05/2025 18:46
Referrer : CITICARE MEDICAL CENTER L.L.C Report Status : **Final Report**
SID.No. : **FD023873** External Visit Id : **46190**
Patient No : **FCL024007**

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
CLINICAL BIOCHEMISTRY				
CITICARE PULSEFIT PACKAGE				
TOTAL CHOLESTEROL / HDL RATIO	3.7	--	< 4.5	Calculation
Serum				

Prepared By



Roshini

Medical Laboratory Technologist



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

Page 4 of 8

End Of The Report

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 18:46
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
CLINICAL BIOCHEMISTRY				
CITICARE PULSEFIT PACKAGE				
BILIRUBIN (TOTAL)	0.2	mg/dL	Up to 1.2	DSA
Serum				
BILIRUBIN (DIRECT)	0.1	mg/dL	0.00 - 0.4	DSA
Serum				
INDIRECT BILIRUBIN	0.10	mg/dL	< or = 0.90	Calculation
Serum				
TOTAL PROTEIN	6.7	g/dL	6 - 8	Biuret
Serum				
ALBUMIN (SERUM)	4	g/dL	3.5 - 4.8	Bromcresol green (BCG)
Serum				
GLOBULIN	2.7	g/dL	2.0 - 3.5	Calculation
Serum				
ALBUMIN / GLOBULIN RATIO	1.48	NULL	0.8 - 2.0	Calculation
Serum				
ALT / SGPT	18.5	U/L	10 - 40	IFCC
Serum				
ALP (ALKALINE PHOSPHATASE)	92.8	U/L	30 - 115	IFCC
Serum				
GGT (GAMMA GLUTAMYL TRANSFERASE)	16.4	U/L	7 - 50	IFCC
Serum				
AST / SGOT	16.1	U/L	10 - 40	IFCC
Serum				

Prepared By



Roshini

Medical Laboratory Technologist



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

Page 5 of 8

End Of The Report

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 18:46
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
ENDOCRINOLOGY				
CITICARE PULSEFIT PACKAGE				
TRIIODOTHYRONINE, TOTAL (T3)	1.41	ng/mL	0.8 - 1.9	CLIA
Serum				
THYROXINE, TOTAL (T4)	7.0	ug/dL	5 - 13	CLIA
Serum				
FOLLICLE STIMULATING HORMONE (FSH)	5.22	mIU/mL	Follicular phase: 2.50 - 11.40 Midcycle Peak: 3.3 - 21.7 Luteal Phase: 1.2 - 7.0 Postmenopausal: 18.8 - 132.0	CLIA
Serum				
LUTEINISING HORMONE (LH)	8.758	mIU/mL	Follicular phase: 1.2 - 12.7 Midcycle Peak: 15.2 - 90.0 Luteal Phase: 0.5 - 14.6 Postmenopausal: 15.6 - 72.0	CLIA
Serum				
PROLACTIN	316.11	uIU/mL	51 - 580	CLIA
Serum				
TESTOSTERONE (TOTAL)	0.23	ng/mL	0.1 - 0.9	CLIA
Serum				
TESTOSTERONE (FREE)	0.006	ng/mL	0.0002 - 0.0085	Calculation
Serum				
SHBG (SEX HORMONE BINDING GLOBULIN)	8.57	nmol/L	Males (17 - 65 Years old) : 13 .77 - 48.94 Females (17 - 65 Years old) : 24.0 - 110.07 Postmenopausal Females : 13.25 to 74.11	CLIA
Serum				
VITAMIN B12	288.912	pg/mL	164 - 905	CLIA
Serum				
VITAMIN D, 25-OH (TOTAL)	16	ng/mL	Deficient : < 20 Insufficient: 20 - 30 Sufficient : 30 - 100 Upper Safety Limit:: > 100	CLIA
Serum				

Prepared By



Gopika

Medical Laboratory Technologist
26832642



Approved By



Dr Anjum Nawshehri
Laboratory Director
DHA-00208333-004

End Of The Report

Page 6 of 8

CONFIDENTIAL LABORATORY REPORT

Patient Name : **Ms. NAHLA**
Age / Sex : 15 Y / Female
DOB :
Referral Doctor :
Referrer : CITICARE MEDICAL CENTER L.L.C
SID.No. : **FD023873**
Patient No : **FCL024007**

Request Date : 21/05/2025 15:26
Collected Date : 21/05/2025 14:57
Acceptance Date : 21/05/2025 15:34
Report Date : 21/05/2025 18:46
Report Status : **Final Report**
External Visit Id : **46190**

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
--------------------------	--------	------	-----------------	--------

ENDOCRINOLOGY

CITICARE PULSEFIT PACKAGE

BETA HCG	0.012	mIU/mL	Non-Pregnant Females: <2.9 Week after LMP 1-10 weeks 195 - 229796 11-15 weeks 22305 - 233036 16-22 weeks 7902 - 49645 23-40 weeks 1580 - 48608	CLIA
----------	--------------	--------	--	------

Serum

Prepared By



Gopika

Medical Laboratory Technologist

26832642



Approved By



Dr Anjum Nawshehri

Laboratory Director

DHA-00208333-004

End Of The Report

Page 7 of 8

CONFIDENTIAL LABORATORY REPORT

Patient Name	: Ms. NAHLA	Request Date	: 21/05/2025 15:26
Age / Sex	: 15 Y / Female	Collected Date	: 21/05/2025 14:57
DOB	:	Acceptance Date	: 21/05/2025 15:34
Referral Doctor	:	Report Date	: 21/05/2025 18:46
Referrer	: CITICARE MEDICAL CENTER L.L.C	Report Status	: Final Report
SID.No.	: FD023873	External Visit Id	: 46190
Patient No	: FCL024007		

INVESTIGATION / SPECIMEN	RESULT	UNIT	REFERENCE RANGE	METHOD
--------------------------	--------	------	-----------------	--------

ENDOCRINOLOGY

CITICARE PULSEFIT PACKAGE

ESTRADIOL (E2)	56.5	pg/mL		CLIA
----------------	------	-------	--	------

Serum

PROGESTERONE	0.437	ng/mL	Follicular Phase : 0.00 - 1.40 Luteal Phase: 3.34 - 25.56 Mid luteal phase: 4.44 - 28.03 Post Menopausal: 0.00 - 0.73 First trimester: 11.22 - 90.0 Second trimester: 25.55 - 89.40 Third trimester: 48.40- 422.50	CLIA
--------------	-------	-------	---	------

Serum

Interpretation Notes : A progesterone test may be used:To help recognize and manage some causes of infertility. Since progesterone levels vary throughout the menstrual cycle, multiple (serial) measurements can be used for this purpose.To determine whether or not a woman has ovulated, when ovulation occurred, or to monitor the success of induced ovulationIn early pregnancy to help diagnose an ectopic or failing pregnancy, along with human chorionic gonadotropin (hCG) testing To monitor a high-risk pregnancy to help evaluate placenta and fetal healthIf a woman is receiving progesterone injections to help support her early pregnancy, to help determine the effectiveness of the replacement treatmentAlong with other tests such as an FSH, LH, hCG, thyroid tests, clotting tests, and a complete blood count (CBC) to help determine the cause of abnormal uterine bleeding in non-pregnant women

Prepared By



Gopika

Medical Laboratory Technologist

26832642



Approved By



Gopika

Medical Laboratory Technologist

26832642

End Of The Report

Page 8 of 8